Cargando…
S133: AN ENTIRELY ORAL REGIMEN OF ORAL-ATO, ATRA AND ASCORBIC ACID IN RISK-ADAPTED TREATMENT OF NEWLY-DIAGNOSED APL RESULTED IN EXCELLENT CLINICAL/MOLECULAR RESPONSES WITH DURABLE REMISSION
Autores principales: | Gill, Harry, Yim, Rita, Chin, Lynn, Lee, Paul, LI, Vivian, Au, Lester, Kit Garret Leung, Man, Kumana, Cyrus, Lam Kwong, Yok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428313/ http://dx.doi.org/10.1097/01.HS9.0000967444.46240.9a |
Ejemplares similares
-
P493: ORAL-ATO/ATRA/ASCORBIC ACID (AAA)-BASED INDUCTION OR MAINTENANCE OF FIRST COMPLETE REMISSION IMPROVED OUTCOMES IN NEWLY DIAGNOSED APL: A MULTICENTRE ANALYSIS OF THE APL ASIAN CONSORTIUM (APLAC)
por: Gill, Harry, et al.
Publicado: (2023) -
Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
por: Gill, Harinder, et al.
Publicado: (2023) -
Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond
por: Kumana, Cyrus R., et al.
Publicado: (2022) -
The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
por: Chin, Lynn, et al.
Publicado: (2022) -
Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside
por: Kumana, Cyrus R., et al.
Publicado: (2020)